摘要
目的探讨CK19和甲状腺过氧化物酶(TPO)在甲状腺癌和良性甲状腺病变中的表达情况,以提高甲状腺癌的诊断和鉴别诊断水平。方法应用SP免疫组织化学法检测了62例甲状腺癌(30例典型乳头状癌、22例滤泡型乳头状癌和10例滤泡型癌)和44例良性甲状腺病变(22例结节性甲状腺肿、14例甲状腺腺瘤和8例桥本氏甲状腺炎)中CK19和TPO的表达。结果CK19在甲状腺癌中表达率为96.8%,在良性甲状腺病变中极少表达或小灶性弱表达,表达率为4.5%,两者有显著性差异(P<0.01);TPO在良性甲状腺病变中的表达率为100%,在甲状腺癌中极少表达或小灶性表达,表达率为3.2%,两者有显著性差异(P<0.01)。结论CK19和TPO在甲状腺癌的病理诊断和鉴别诊断中具有重要意义和临床实用价值。
Objective To investigate the value of detecting cytokeratin 19(CK19) and thyroperoxidase (TPO) expression in the diagnosis of thyroid diseases including thyroid carcinoma, multinodular goiter, adenoma and Hashimoto thyroiditis. Methods SP immunohistochemistry was used to detect the expressions of CK19 and TPO in paraffin-embedded thyroid tissue specimens obtained from 62 patients with thyroid carcinoma (30 with papillary carcinomas, 22 with follicular variant of papillary carcinomas, and 10 with follicular carcinomas) and 44 with benign thyroid diseases (including 22 with multinodular goiters, 14 with adenoma, and 8 with Hashimoto thyroiditis). Results CK19 expression was detected in 96.8% of the thyroid carcinomas and in 4.5% of benign thyroid diseases, demonstrating a significant difference in CK19 expression between the two thyroid diseases (P<0.01). TPO expression was found in 100% of benign thyroid disease and in 3.2% of thyroid carcinoma, showing also a significant difference between them (P<0.01). Conclusion CK19 and TPO can be important molecular markers for diagnosing thyroid carcinoma.
出处
《第一军医大学学报》
CSCD
北大核心
2005年第6期678-681,共4页
Journal of First Military Medical University
基金
广东省医学科研基金(A2004753)~~
